Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00517790 | Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) | PHASE2 | COMPLETED | 140 | — | — | Aug 1, 2007 | Jun 1, 2012 | Apr 5, 2013 | 28 | United States, Canada +3 |
| Arm | Type | Description |
|---|---|---|
| ABT-869 0.25 mg/kg | EXPERIMENTAL | Approximately half of the subjects were randomized to receive the high dose |
| ABT-869 0.10 mg/kg | EXPERIMENTAL | Approximately half of the subjects were randomized to receive the Low Dose |
| Name | Type | Description |
|---|---|---|
| ABT-869 .25 mg/kg | DRUG | Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight. |
| ABT-869 0.10 mg/kg | DRUG | Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight. |
Inclusion Criteria: * Subject must be histologically or cytologically diagnosed with advanced or metastatic NSCLC * Subjects must have at least one lesion measurable by CT scan as defined by RECIST * The measurable lesion may have not received radiation therapy * Subject has an Eastern Cooperative ...